{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:20:29Z","timestamp":1777486829290,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":548,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.exphem.2022.03.012","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T20:54:17Z","timestamp":1648846457000},"page":"60-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4078-5087","authenticated-orcid":false,"given":"Seung Yeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-4136","authenticated-orcid":false,"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Young","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6162-5571","authenticated-orcid":false,"given":"Jung Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2022.03.012_bib0001","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2022.03.012_bib0002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5045\/kjh.2012.47.1.28","article-title":"Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008","volume":"47","author":"Park","year":"2012","journal-title":"Korean J Hematol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0003","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple myeloma, version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.exphem.2022.03.012_bib0004","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.03.012_bib0005","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.012_bib0006","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial","volume":"37","author":"Gay","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0007","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.012_bib0008","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2022.03.012_bib0009","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.5045\/br.2020.S007","article-title":"Frontline therapy for newly diagnosed patients with multiple myeloma","volume":"55","author":"Jung","year":"2020","journal-title":"Blood Res"},{"key":"10.1016\/j.exphem.2022.03.012_bib0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA\u2013ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0011","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/EDBK_239067","article-title":"Approach to the older adult with multiple myeloma","volume":"39","author":"Mina","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.exphem.2022.03.012_bib0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.012_bib0013","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.03.012_bib0014","first-page":"140","article-title":"Lenalidomide) now FDA approved as first-line therapy for patients with multiple myeloma","volume":"9","author":"Revlimid","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.exphem.2022.03.012_bib0015","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/cancers13061353","article-title":"Immune system alterations in multiple myeloma: molecular mechanisms and therapeutic strategies to reverse immunosuppression","volume":"13","author":"D\u00edaz-Tejedor","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2022.03.012_bib0016","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0017","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00262-016-1861-2","article-title":"Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory\/relapsed multiple myeloma","volume":"65","author":"Lee","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2022.03.012_bib0018","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.exphem.2022.03.012_bib0019","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2022.03.012_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/cei.12196","article-title":"Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy","volume":"175","author":"Chan","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0021","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-021-00440-4","article-title":"Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2022.03.012_bib0022","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/2326-6066.CIR-20-0663","article-title":"Myeloma-secreted galectin-1 potently interacts with CD304 on monocytic myeloid-derived suppressor cells","volume":"9","author":"Lim","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.exphem.2022.03.012_bib0023","doi-asserted-by":"crossref","first-page":"73","DOI":"10.15283\/ijsc18094","article-title":"Predictive role of circulating immune cell subtypes early after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia","volume":"12","author":"Kim","year":"2018","journal-title":"Int J Stem Cells"},{"key":"10.1016\/j.exphem.2022.03.012_bib0024","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple Myeloma","volume":"23","author":"Philip","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0025","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0026","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2014.110","article-title":"Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.03.012_bib0027","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.012_bib0028","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.exphem.2022.03.012_bib0029","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.coi.2004.01.004","article-title":"Development and function of CD25+CD4+ regulatory T cells","volume":"16","author":"Feh\u00e9rvari","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0030","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1038\/s41467-021-25009-4","article-title":"MAIT cells regulate NK cell-mediated tumor immunity","volume":"12","author":"Petley","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2022.03.012_bib0031","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0032","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/bcj.2015.32","article-title":"The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2022.03.012_bib0033","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2141.2002.03879.x","article-title":"Anti-myeloma activity of natural killer lymphocytes","volume":"119","author":"Frohn","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0034","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2257.1994.tb00414.x","article-title":"Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"16","author":"Tienhaara","year":"1994","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.03.012_bib0036","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.012_bib0037","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/hemato2020010","article-title":"Role and modulation of NK cells in multiple myeloma","volume":"2","author":"Rubio","year":"2021","journal-title":"Hemato"},{"key":"10.1016\/j.exphem.2022.03.012_bib0038","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","article-title":"Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation","volume":"143","author":"Shi","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0039","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0040","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1250051","article-title":"Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma","volume":"5","author":"Leivas","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.exphem.2022.03.012_bib0041","doi-asserted-by":"crossref","first-page":"7983","DOI":"10.1002\/jcp.27553","article-title":"Contribution of regulatory T cells to cancer: a review","volume":"234","author":"Najafi","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0042","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional CD4+PD-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2022.03.012_bib0043","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-021-01422-y","article-title":"Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression","volume":"36","author":"Dahlhoff","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.03.012_bib0044","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12885-019-6499-y","article-title":"Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells","volume":"20","author":"Yoshida","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2022.03.012_bib0045","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2022.03.012_bib0046","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 inhibitors in multiple myeloma","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0047","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s12185-021-03201-y","article-title":"Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis","volume":"114","author":"Suzuki","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0048","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41408-017-0019-6","article-title":"The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents","volume":"7","author":"Romano","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2022.03.012_bib0049","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1038\/bcj.2017.60","article-title":"Significance of the absolute lymphocyte\/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma","volume":"7","author":"Dosani","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2022.03.012_bib0050","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00277-015-2462-4","article-title":"Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents","volume":"94","author":"Romano","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0051","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.012_bib0052","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood.V54.1.226.226","article-title":"In vitro cytotoxic response to human myeloma plasma cells by peripheral blood leukocytes from patients with multiple myeloma and benign monoclonal gammopathy","volume":"54","author":"Paglieroni","year":"1979","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.03.012_bib0053","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/cells8121526","article-title":"Tumor-associated macrophages in hematologic malignancies: new insights and targeted therapies","volume":"8","author":"Petty","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.exphem.2022.03.012_bib0054","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/183602","article-title":"Multiple myeloma macrophages: pivotal players in the tumor microenvironment","volume":"2013","author":"Berardi","year":"2013","journal-title":"J Oncol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41409-019-0681-3","article-title":"Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant","volume":"55","author":"Sweiss","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2022.03.012_bib0056","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","article-title":"NK cell-based immunotherapy for cancer","volume":"31","author":"Fang","year":"2017","journal-title":"Semin Immunol"},{"key":"10.1016\/j.exphem.2022.03.012_bib0057","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-065X.2006.00445.x","article-title":"The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression","volume":"214","author":"Ghiringhelli","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1016\/j.exphem.2022.03.012_bib0058","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12977-015-0191-3","article-title":"Activated regulatory T cells suppress effector NK cell responses by an IL-2-mediated mechanism during an acute retroviral infection","volume":"12","author":"Littwitz-Salomon","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.exphem.2022.03.012_bib0059","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.20051511","article-title":"CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner","volume":"202","author":"Ghiringhelli","year":"2005","journal-title":"J Exp Med"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22001321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22001321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:37:20Z","timestamp":1759567040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X22001321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":59,"alternative-id":["S0301472X22001321"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2022.03.012","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2022.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}